<DOC>
	<DOC>NCT00108979</DOC>
	<brief_summary>Escitalopram is the S-enantiomer of citalopram. Both escitalopram and citalopram are selective serotonin reuptake inhibitors (SSRIs) and are used to treat depression in adults. This study is designed to evaluate the efficacy, safety, and pharmacoeconomics of escitalopram and an active comparator in patients with major depressive disorder.</brief_summary>
	<brief_title>Study of Escitalopram in Adult Patients With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Patients must meet Diagnostic and Statistical Manual, Fourth Edition (DSMIV) diagnostic criteria for Major Depressive Disorder. The patient's current depressive episode must be at least 12 weeks in duration. Women who are pregnant, women who will be breastfeeding during the study, and women of childbearing potential who are not practicing a reliable method of birth control. Patients who currently meet DSMIV criteria for: a. bipolar disorder; b. schizophrenia or any psychotic disorder; c. obsessivecompulsive disorder; d. mental retardation or any pervasive developmental disorder or cognitive disorder. Patients who are considered a suicide risk. Patients with a history of seizure disorder, or any history of seizure, stroke, significant head injury, or any other condition that predisposes toward risk of seizure.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Depression</keyword>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Escitalopram</keyword>
</DOC>